Rodger Novak - 21 Jun 2021 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Signature
/s/ Michael Esposito, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
21 Jun 2021
Transactions value $
$-3,215,458
Form type
4
Filing time
23 Jun 2021, 17:54:30 UTC
Next filing
30 Jun 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Sale $-147,054 -1,171 -0.18% $125.58 646,836 21 Jun 2021 Direct F1, F2
transaction CRSP Common Shares Sale $-111,552 -881 -0.14% $126.62 645,955 21 Jun 2021 Direct F1, F3
transaction CRSP Common Shares Sale $-379,171 -2,969 -0.46% $127.71 642,986 21 Jun 2021 Direct F1, F4
transaction CRSP Common Shares Sale $-1,626,239 -12,630 -1.96% $128.76 630,356 21 Jun 2021 Direct F1, F5
transaction CRSP Common Shares Sale $-944,929 -7,299 -1.16% $129.46 623,057 21 Jun 2021 Direct F1, F6
transaction CRSP Common Shares Sale $-6,514 -50 -0.01% $130.27 623,007 21 Jun 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.095 to $126.08, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.175 to $127.175, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.19 to $128.19, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.195 to $129.195, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.20 to $130.11, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.